ABSTRACT
Diabetes mellitus is associated with macro-and micro-angiopathy, leading to increased risk of peripheral ischemia. In the present study, we have characterized the microvascular phenotype at the level of limb muscles and the spontaneous angiogenesis response to surgicallyinduced unilateral limb ischemia in a murine model of type-2 diabetes, the obese C57BL/KsOlaHsd-Lepr db/db mice (Lepr db/db ), and in non-diabetic heterozygous Lepr db/+ . Wild type C57BL mice (WT) were used as controls. The basal microvascular phenotype was determined in mice aged 3 or 5 months, while the response to limb ischemia was studied only in 5-month old mice. Moreover, in 5 In type-2 diabetic patients, therapeutic angiogenesis may need to be further optimized before being recommended for clinical applications.
INTRODUCTION
Type-2 diabetes accounts for 90-95% of all diabetes. The disorder affects around 6% of the adult population in industrialized countries and its worldwide prevalence is expected to increase at the rate of 6% per year, reaching a total of 200-300 million cases by 2010 (1,2). Type-2 diabetes is associated with endothelial dysfunction, atherosclerotic macrovascular disease, and microangiopathy. As a consequence, patients show a much higher risk of limb amputation, myocardial infarction, and stroke. Cardiovascular complications are eventually responsible for 80% of casualties and more than 75% of all hospitalizations related to diabetes (3).
Diabetes
impairs the reparative neovascularization response to arterial occlusion, thus accounting for the worse clinical outcome of diabetic patients following an ischemic accident (4). Supply-side approaches with angiogenic substances or endothelial cell (EC) precursors have been successfully applied for rescuing ischemia in type-1 diabetic rodents (5-7). In addition, prophylactic delivery of the human tissue kallikrein gene (hTK) reportedly halts the progression of microvascular rarefaction in adductor muscles of streptozotocin-induced type-1 diabetic mice (8) and ensures an improved haemodynamic recovery in case of supervening arterial occlusion (9) . However, the successes achieved by therapeutic angiogenesis in mice, dogs and pigs have not been replicated by clinical trials completed to date (10) . One major reason for these discrepancies consists of the fact that models relying on young, mildly compromised animals might be inadequate to reproduce the real situation of patients with advanced occlusive arterial disease and associated risk factors.
Appropriate models should therefore be considered in order to obtain unequivocal proof of efficacy before clinical testing.
The present study was conducted in the type-2 diabetic and obese C57BL/KsOlaHsd-Lepr . In previous work, we showed that hTK potently stimulates angiogenesis through kininmediated activation of the PI3K-Akt-NO pathway (18, 19) . Akt, a kinase that lies downstream of various proangiogenic and anti-apoptotic agents (20) (21) (22) (23) (24) (25) (26) , reportedly promotes reparative angiogenesis in animal models (27 , Harlan, Milan, Italy) and non-diabetic Lepr db/+ were studied at 3 and 5 months of age. Age-matched wild type C57BL (WT) mice served as controls. Body weight (BW), fasting plasma glucose levels, and glycosuria were monitored throughout the study.
Assessment of the Time Course of Microangiopathy
Adductor capillary density and arteriole profile and density were determined, as previously described (8, 9, 16) , in mice aged 3 or 5 months (n=8 mice per group). At the same time points, apoptosis of EC and myofiber was evaluated by a terminal deoxynucleotidyl transferasemediated dUTP nick end labelling (TUNEL) assay on paraffin-embedded muscular sections, as described (8,18).
Gene Constructs
Adenovirus (Ad) carrying hTK (Ad.CMV-hTK) (28) or the constitutively-active mutant Myr-Akt (Ad.MyrAkt-B) (29) was used. An adenovirus harbouring the luciferase gene (Ad.CMV-Luc) served as a control.
Ischemia Model and Gene Delivery
Left limb ischemia was induced in anaesthetized (2,2,2-tribromoethanol -avertin-, 880 mmol/kg body wt IP, Sigma-Aldrich, Italy) Lepr db/db , Lepr db/+ , and WT mice. To this aim, the left femoral artery was dissected free from the femoral vein and nerve and it was ligated with 6.0 silk just below the inguinal ligament. The arterial segment (0.5 mm in length) below the ligation was electrocoagulated. This operative procedure is suited to limit spontaneous autoamputation rate and avoid sufferance to the animals (9). In another experiment, 5- Western blot for phosphorylated AktS473 (Cell Signalling, 1:1000) and total Akt (Cell Signalling, 1:1000) was performed on proteins extracted from Ad.Myr.Akt-and Ad.Luc-injected muscles. The housekeeping protein GAPDH (RDI, 1:1000) was used as a loading control.
Quantitavive PCR for Measuring Muscular eNOS and VEGF-A content
Real-time quantitative PCR (ABI PRISM  7000
Sequence Detection System software version 1.0., Perkin Elmer) with internal standards was used to determine eNOS and VEGF-A mRNA content in ischemic (at 3 days postischaemia induction) and contralateral muscles of Lepr db/db , Lepr db/+ , and WT (n=4 to 5 mice per group). We also measured the mRNA levels of eNOS and VEGF-A in ischemic muscles of Lepr db/db which had received Ad.hTK, Ad.Myr-Akt, or Ad.Luc (n=5 mice per group). ENOS and VEGF-A were normalized to GAPDH levels. All procedures (including PCR primers and internal standards) have been described previously (19).
Haemodynamic Measurements and Assessment of the Clinical Outcome
Systolic blood pressure (SBP) and heart rate (HR) were measured in unanesthetized mice by tail-cuff plethysmography (Visitech Systems) (30) . Blood flow (BF) to the hindlimbs was measured by laser Doppler flowmetry (Lisca Inc., Sweden). BF measurements were performed on anesthetized mice prior to surgery and weekly thereafter. To determine the rate of blood flow (BF) recovery to the ischemic foot, the ischemic to non-ischemic foot BF ratio was calculated. The rate of foot autoamputation was evaluated at 14 days from ischemia.
Histological Analyses of Ischemic Muscles
At 2 weeks post-ischemia, anesthetized mice (n=8 per group) were perfusion-fixed. Adductor muscles were harvested and processed for analysis of capillary and arteriole density and apoptosis.
Statistical Analysis
All results are expressed as mean±SEM. Statistical analyses were performed by the Sigmastat program. One-way ANOVA for comparison among groups were performed. In case ANOVA indicated significant difference among groups, Tukey post test was used to check for difference between groups. A P value <0.05 was interpreted to denote statistical significance.
RESULTS

Cardiovascular Phenotype of Lepr db/db
As shown in Table 1 
Microangiopathy of Lepr db/db
In limb muscles of 3-and 5-month old Lepr db/db , capillary density was lower than in WT (P<0.01 for both comparisons) ( Figure 1A ). Similarly reduced (P<0.01) was the capillary to myofiber ratio ( Figure 1B) . Lepr db/+ showed normal adductor muscle capillarity (p=N.S. vs WT for comparisons at 3 and 5 months). As shown in Figure  1C, Figure 1D ). In Lepr db/db , apoptosis was also activated at myofiber level (26±4 vs 6±1 TUNELpositive myofibers/mm 2 in WT, P<0.01, Figure 1D ). In Lepr db/+ , the number of apoptotic ECs did not differ from the figure seen in WT at 3 months. However, EC apoptosis was increased at 5 months (P<0.01 vs WT, Figure 1D ). Capillary and arteriole density was normal in the muscles of 3-and 5-month old Lepr db/+ .
Impaired Reparative Angiogenesis in Lepr db/db
We then examined the ability of 5-month old Lepr db/db and Lepr db/+ to mount a spontaneous reparative angiogenesis response to interruption of femoral blood flow. Ischemic WT were used for reference. As shown in Figure 2 
Impaired Clinical Outcome and Delayed Haemodynamic Recovery in Lepr db/db
As shown in Figure 5A, Figure 5B. 
Down-regulation of VEGF-A and eNOS in Ischemic Limb Muscles of Lepr db/db
As shown in Figure 6 , the VEGF-A mRNA level was 1.9-fold lower in ischemic muscles of Lepr db/db compared with WT (P<0.05). VEGF-A expression was As shown in Figure 7A , hTK mRNA was present in Ad.hTK-injected Lepr db/db muscles, whereas no hTK gene product was present in samples obtained from Ad.Lucgiven adductors. As shown in Figure 7B , Ad.Myr-Aktinjected muscles showed increased content of both phosphorylated AktS473 (phosphorylated AktS473 to GAPDH densitometry ratio: 1.42±0.14 in Ad.Myr.Akt vs 0.8±0,20 in Ad. Null, P<0.05) and total Akt (total Akt to GAPDH densitometry ratio: 1.05±0.13 in Ad.Myr.Akt vs 0.57±0.02 in Ad. Null, P<0.01).
As shown in Figure 8, , hTK-or Akt-induced neovascularization translated into improved recovery of BF to the ischemic muscles (see Figure 9A) . In strict contrast, in Lepr db/db , angiogenesis gene therapy with either hTK or Myr.Akt completely failed to ameliorate BF recovery (see Figure 9B) .
Neither of the clinical outcome was ameliorated by gene therapy (data not shown).
DISCUSSION
In this study, we have shown that type-2 diabetic and obese Lepr db/db are affected by limb muscle microangiopathy, consisting of rarefaction of capillaries and arterioles which is likely attributable to apoptotic loss of vascular cells. These animals are also characterized by impaired reparative neovascularization and delayed blood flow recovery following experimentally-induced limb ischemia.
Heterozygous Lepr db/+ showed a milder phenotype, with EC apoptosis being activated at later stages.
The capillary rarefaction that we have observed in Lepr db/db might significantly contribute to alter the path length for oxygen transport to myocytes, thus, ultimately leading to ischemia and additional activation of cell-death mechanisms.
Accordingly, myofiber apoptosis was observed in Lepr db/db . Detrimental haemodynamic effects and tissue hypoxia may derive from the rarefaction of arterioles, the conduit vessels that normally provide the largest part of tissue blood flow.
Thus, the microangiopathy observed in Lepr db/db recalls the structural alterations described previously in type-2 diabetic patients (34) . The observation that microvascular alterations were associated with normal blood pressure levels discount a possible influence of haemodynamic factors on microangiopathy. However, we cannot exclude that, as a consequence of vascular rarefaction and remodeling causing an increase in peripheral vascular resistances, hypertension may develop in elderly Lepr db/db .
Another common clinical feature of diabetic patients is the failure to mount a proper collateralization in response to arterial occlusion, thus resulting in delayed tissue healing and recurrent ischemia (4) . Similarly, reparative angiogenesis response was severely impaired in Lepr db/db and associated with arteriole remodeling and thrombosis. The latter phenomena are likely to account for inadequate reperfusion and excess of foot necrosis that we have observed in this strain. Impaired post-ischemic recovery of Lepr db/db was previously reported by us and, later, by Schiekofer et al (16, 17) . These preliminary observations have been significantly expanded by the present study, showing arterial remodeling, intra-luminal thrombosis, and uniquely activated apoptosis in vascular and muscular cells of Lepr db/db limb muscles following arterial occlusion. We have also evaluated the effect of heterozygosity on angiogenesis, showing the existence of a gene titration effect.
The mRNA contents of VEGF-A and eNOS were reduced in the ischemic muscles of diabetic mice, thus supporting the possibility that the leptin signalling may be important for the native modulation of angiogenic effectors. This is in keeping with previous observations showing that leptin increases eNOS phosphorylation in Ser 1177 and stimulates NO release by cultured ECs and isolated vessels (32) . However, diabetes-induced endothelial dysfunction and/or microvessel rarefaction, independent of the leptin knock-out, may, per se, have contributed to the expressional changes observed in Lepr db/db . Lepr db/+ showed a mildly reduced haemodynamic recovery and impaired ischemia-induced eNOS up-regulation. In apparent contradiction with the finding of Schiekofer et al (17) , VEGF-A was not up-regulated by ischemia in our wild type mice. However, the time points chosen by Schiekofer and colleagues to perform mRNA analyses differ from ours. We worked at 3 days post-ischemia. The other group worked at 1, 7, and 14 days thereafter. It is noteworthy that they could find ischemia-induced VEGF-A mRNA upregulation only at 7 days or later. As angiogenesis is a phenomenon which develops early after ischemia and increases in capillary density are already appreciable after 7 days (18), the probability that gene expressional changes at 7 days account for post-ischemic angiogenesis may be considered scarce. On the other hand, in agreement with previous findings that endogenous eNOS is essential for post-ischemic angiogenesis (35, 36) , we found increased eNOS mRNA levels in the ischemic muscles of wild type An important finding of this study consists of the unexpected result that angiogenesis gene therapy with either hTK or constitutively activated Akt failed to improve the blood flow recovery in the Lepr db/db . This failure occurred despite the potent pro-angiogenic and proarteriogenic effects exerted by either gene transfer approach.
We have previously shown that intra-muscular hTK gene transfer, exert a potent therapeutic effect in the limb muscles of normoglycemic or type-1 diabetic mice with peripheral ischemia (9, 18) . One of the kallikrein products, bradykinin activates eNOS via the PI3K-Akt and calcineurin pathways (39) . In vivo, we showed that hTK activates Akt-NO pathway by a VEGF-independent mechanism (19) .
Moreover, Akt gene transfer was previously shown to induce therapeutic angiogenesis and to ameliorate the BF to ischemic limbs (27) , thus further supporting proper experimental procedures. More importantly, in non obese and non diabetic heterozygous mice, the same gene therapies did improve blood flow recovery. Having discounted for technical problems, the other possible explanation of the negative results observed in Lepr db/db would be the intrinsic unresponsiveness to pro-angiogenesis treatment as the sole way to address vascular liabilities. Specifically, although numerically augmented, the newly generated vessels of diabetic mice might be dysfunctional, as recently reported by our group (42) and prone to thrombosis. In addition, diabetic myopathy could be refractory to de novo neovascularization.
In conclusion, our results suggest that stimulation of neovascularization might not suffice as a sole therapeutic avenue to combat type-2 diabetes-related vascular complications. Therapeutic angiogenesis might represent a complement, rather than an alternative, to a global treatment strategy including extreme revascularization, anti-oxidant agents, and metabolic control of hyperglycemia for the cure of diabetes complications. Consequently, angiogenesis gene therapy needs further preclinical optimization in appropriate animal models to improve the chances of clinical success.
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